All In Biotech

Drug Trial Radar · NCT00582582

Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer

Phase II Evaluation of Docetaxel Randomized With Doxercalciferol or Placebo in Patients With Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Dec 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

70

Actual

Start

Apr 2002

Primary completion

Not stated

Study completion Apr 2007

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi; Genzyme, a Sanofi Company
First posted
Dec 28, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to find out the toxicities of doxercalciferol given in combination with docetaxel (Taxotere®), as well as to see how well this combination works in the treatment of prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • Docetaxel plus doxercalciferolDrug

    Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day

  • Docetaxel plus placeboDrug

    Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: At 12 weeks on study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.